Annuaire
M. Pierre Coursaget
Coordonnées
Thèmes de recherche
Papillomavirus, Polyomavirus, virus de l'hépatite E. Transfert de gènes à l'aide de capsides virales.
Activités / CV
Publications récentes:
- Fleury M, Touzé A, Maurel MC, Moreau T, Coursaget P. Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci. 2009, 18:1425-1438.
- Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009, 9:347-56.
-Touzé A, Gaitan J, Maruani A, Lebidre E, Doussinaud A, Clavel C, Durlach A, Aubin F, Guyetant S, Lorette G, Coursaget P. Merkel cell polyomavirus strains in patients with Merkel cell carcinoma. Emerg Infect Dis, 2009, 15: 960-962
- Bousarghin L, Touzé A, Gaud G, Iochmann S, Alvarez E, Reverdiau P, Gaitan J, Jourdan ML, Sizaret PY, Touzé A, Coursaget P. Inhibition of cervical cancer cells growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther, 2009, 8 : 357-365.
- Renoux V, Fleury M, Bousarghin L, Gaitan J, Sizaret PY, Touzé A, Coursaget P. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice. Vaccine 2008, 26: 6602-6607.
- Fernández-San Millán A, Ortigosa SM, Hervás-Stubbs S, Corral-Martínez P, Seguí-Simarro JM, Gaitan J, Coursaget P, Veramendi J. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J. 2008, 6:427-41.
- Fleury MJ, Touzé A, de Sanjosé S, Bosch FX, Klaustermeiyer J, Coursaget P. Detection of neutralizing antibodies against human papillomavirus type 31 after natural infection using an assay based on intracellular assembly of luciferase-expressing pseudovirions. Clinical and Vaccine Immunology. 2008, 15 : 172-175.
- Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009, 9:347-56.
-Touzé A, Gaitan J, Maruani A, Lebidre E, Doussinaud A, Clavel C, Durlach A, Aubin F, Guyetant S, Lorette G, Coursaget P. Merkel cell polyomavirus strains in patients with Merkel cell carcinoma. Emerg Infect Dis, 2009, 15: 960-962
- Bousarghin L, Touzé A, Gaud G, Iochmann S, Alvarez E, Reverdiau P, Gaitan J, Jourdan ML, Sizaret PY, Touzé A, Coursaget P. Inhibition of cervical cancer cells growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther, 2009, 8 : 357-365.
- Renoux V, Fleury M, Bousarghin L, Gaitan J, Sizaret PY, Touzé A, Coursaget P. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice. Vaccine 2008, 26: 6602-6607.
- Fernández-San Millán A, Ortigosa SM, Hervás-Stubbs S, Corral-Martínez P, Seguí-Simarro JM, Gaitan J, Coursaget P, Veramendi J. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J. 2008, 6:427-41.
- Fleury MJ, Touzé A, de Sanjosé S, Bosch FX, Klaustermeiyer J, Coursaget P. Detection of neutralizing antibodies against human papillomavirus type 31 after natural infection using an assay based on intracellular assembly of luciferase-expressing pseudovirions. Clinical and Vaccine Immunology. 2008, 15 : 172-175.